echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > JBMR: The effect of Odanacatib on bone structure and quality of postmenopausal women with osteoporosis

    JBMR: The effect of Odanacatib on bone structure and quality of postmenopausal women with osteoporosis

    • Last Update: 2021-09-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


     Odanacatib (ODN) is an oral selective cathepsin K (CatK) inhibitor for osteoporosis.


    Compared with placebo, the proportion of periosteal double-label patients and bone formation index in ODN-treated patients increased over time


    In summary, ODN treatment for 5 years did not reduce bone remodeling, and increased the proportion of patients with periosteal bone formation .


    ODN treatment for 5 years did not reduce bone remodeling, and increased the proportion of patients with periosteal bone formation .


    Source: Robert Recker, MD1, David Dempster, PhD2, Bente Langdah, Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women with Osteoporosis: 5-year Data from the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension , J Bone Miner Res 2020 07;35(7) 



    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.